Doctors and patients are increasingly demanding not just accuracy from diagnostic equipment, but mobility, intelligence, and affordability. In 2026, the Russian functional diagnostics market is experiencing a real boom — from portable ECG monitors to ultrasound machines with artificial intelligence. But behind the bright new products lie strict regulatory changes that are already determining who will survive and who will leave the market.
What Happened? Why Is This Important?
Starting in September 2026, all electrocardiographs, encephalographs, ultrasound machines, and spirometers must be registered under the unified EAEU rules. Old Russian certificates are no longer valid — they cannot be renewed. For manufacturers, this means that even a delay of a couple of months could lead to the seizure of batches from circulation. However, there is good news: the regulator has made a number of concessions for those ready to play by the new rules.
Key Changes You Cannot Ignore:
-
Home diagnostics have become easier. Portable electrocardiographs with Holter monitors, compact spirometers, and point-of-care ultrasound devices can now undergo expert review in50 working days instead of six months. The main condition is having an ISO 13485 certificate and documents from any EAEU country.
-
AI algorithms require separate registration. If your ultrasound machine or encephalograph interprets data on its own (for example, detects arrhythmia or looks for spikes in epilepsy), the software must be registered as a separate medical device. This is more expensive, but it grants access to a priority expert review track — one month faster.
-
Mutual recognition: a life hack for a quick start. Manufacturers who have already registered a device in Kazakhstan or Belarus can avoid repeated clinical trials in Russia. It is enough to submit an application with a validation report and an ISO 13485 certificate. Real-life example: a company from Novosibirsk brought a Bluetooth ECG to market in45 working days and saved almost 850 thousand rubles.
-
Ban on "old" chemicals. As of 2026, sodium azide and thiomersal in electrode gels and contact fluids for ECGs and ultrasounds are banned. Manufacturers using such compositions urgently need to change their formulations — otherwise, registration will not be renewed.
What Will Be Trending in the Next Two Years?
- "Diagnostics + Telemedicine" hybrids. Spirometers with built-in pulse oximeters and secure data transmission to a doctor — such devices are already being developed by dozens of startups. For them, Roszdravnadzor has announced a separate simplified track starting in the fall of 2026.
- Ultrasound screening with AI. Automatic liver segmentation, pregnancy assessment — by October 2026, such algorithms will require a mandatory report under GOST R 59977-2026. This will complicate life for developers but increase trust among doctors.
- Home encephalographs. Devices for monitoring epilepsy are gaining popularity. But now they face strict accuracy requirements (at least 95% sensitivity) and mandatory usability studies.
How Not to Be Late: A Primer for Manufacturers
If you want to bring an electrocardiograph, ultrasound machine, or spirometer to market in 2026, here are four steps you need to take right now:
- Determine your device's risk class (I, IIa, IIb, or III). This determines the scope of testing and timelines.
- Prepare documentation in Russian, including a description of the software — especially if it contains AI modules.
- Obtain a valid ISO 13485 (not older than3 years) — without it, the simplified procedure is unavailable.
- Develop packaging with a QR code — this requirement came into force in April 2026.
The Main Thing: Don't Wait.
There is currently a unique window on the market: mutual recognition, no mandatory clinical trials for portable devices, and a priority track for AI products make registration faster and cheaper than ever. But the concessions are not forever — the simplified procedure is valid only until 2028, and the unified EAEU registry will go into effect as early as September 2026. Those who make it in time will gain priority access to the markets of five countries.
